|1.||Rigas, Basil: 3 articles (03/2009 - 01/2008)|
|2.||Mackenzie, Gerardo G: 1 article (03/2009)|
|3.||Zhang, Zhiquan: 1 article (03/2009)|
|4.||Murray, Onika T: 1 article (03/2009)|
|5.||Zhao, Wenping: 1 article (03/2009)|
|6.||Sun, Yu: 1 article (10/2008)|
|7.||Kozoni, Vasiliki: 1 article (01/2008)|
01/01/2008 - "We conclude that phosphoaspirin is a promising agent for the control of cancer that deserves further evaluation."
01/01/2008 - "Phosphoaspirin achieved this effect by modulating cell kinetics; the proliferation index of cancer cells was reduced by 18.13% compared to controls (p<0.001) and the apoptosis index was increased by 94.6% (p<0.003). "
01/01/2008 - "The size of the tumors decreased progressively in the phosphoaspirin treated group, compared to controls, being reduced by 57% (p<0.001) on day 21. "
03/01/2009 - "Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect."
01/01/2008 - "Phosphoaspirin (100 mg/kg body weight intraperitoneally daily for 21 days) also inhibited the growth of HT-29 tumors grown as xenografts in nude mice. "
|2.||Colonic Neoplasms (Colon Cancer)
|3.||Body Weight (Weight, Body)
|1.||Aspirin (Acetylsalicylic Acid)
|2.||Nitric Oxide (Nitrogen Monoxide)
|3.||Arsenicals (Arsenic Compounds)
|1.||Heterologous Transplantation (Xenotransplantation)